Newamsterdam Pharma Company ($NAMS)

2 tracked superinvestors hold Newamsterdam Pharma Company (NAMS), worth $233M combined, led by Andreas Halvorsen. Smart money is holding NAMS as of the latest 13F filings.

Current price

$35.92

BiotechnologyNASDAQNL

+60.1%

1Y

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same…

Market cap

$3.3B

P/E

-16.53

Div yield

0.0%

Revenue YoY

-50.6%

Analyst target

$50

Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.

Superinvestors holding

2

tracked 13F / N-PORT funds

Combined value

$233M

disclosed long exposure

Tier-1 conviction

2

concentrated holders

Net this quarter

0

0 buying · 0 selling

Smart money is holding NAMS steady this quarter — buys and sells are balanced.

The smart-money take on NAMS

Newamsterdam Pharma Company (NAMS) is held by 2 tracked funds worth $233M combined, 2 of them concentrated Tier-1 managers whose positions carry real conviction.

The largest position belongs to Andreas Halvorsen at 0.4% of their book — no single tracked manager treats it as an outsized, top-weighted bet.

Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.

Superinvestors holding NAMS

InvestorMove% of their portfolioPosition value
1
Andreas Halvorsen

Viking Global Investors

Held0.4%$135M
1
Stanley Druckenmiller

Duquesne Family Office

Held2.9%$98M

Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.

Frequently asked

Which superinvestors own NAMS?

2 tracked funds hold Newamsterdam Pharma Company (NAMS), the largest being Andreas Halvorsen (Viking Global Investors) at 0.4% of its 13F portfolio. 2 of them are concentrated Tier-1 conviction managers.

Is smart money buying or selling NAMS?

In the most recent 13F quarter, 0 tracked funds added or opened NAMS and 0 trimmed it.

How much NAMS do tracked funds hold?

Combined disclosed long exposure to NAMS across tracked superinvestors is $233M as of the Mar 2026 filings.

Stocks often held alongside NAMS

Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.